MDS 2023 | PevAz update: pevonedistat & azacitidine in R/R MDS and MDS/MPN after DNMTi failure
Michael Savona, MD, Vanderbilt University Medical Center, Nashville, TN, gives an update on the Phase II PevAz study (NCT03238248) investigating the addition of pevonedistat to azacitidine after DNA methyltransferase inhibition (DNMTi) failure in relapsed/refractory (R/R) myelodysplastic syndromes (MDS) and MDS/myeloproliferative neoplasm (MPN) overlap syndromes. Whilst response rates (RRs) were modest, patients achieved a median survival of approximately 18 months, suggesting that pevonedistat might have a role in this patient population. This interview took place at the 17th International Congress on Myelodysplastic Syndromes 2023 (MDS 2023) held in Marseille, France.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Karyopharm: Consultancy, Current equity holder in publicly-traded company, Membership on an entity’s Board of Directors or advisory committees; Ryvu: Consultancy, Current equity holder in publicly-traded company, Membership on an entity’s Board of Directors or advisory committees; Sierra Oncology: Other: serves on Data and Safety Monitoring Boards; TG Therapeutics: Research Funding; Incyte: Research Funding; Astex: Research Funding; Takeda: Membership on an entity’s Board of Directors or advisory committees, Research Funding; Taiho: Membership on an entity’s Board of Directors or advisory committees; Novartis: Membership on an entity’s Board of Directors or advisory committees; Geron: Membership on an entity’s Board of Directors or advisory committees; AbbVie: Membership on an entity’s Board of Directors or advisory committees; Forma: Consultancy; BMS: Consultancy, Membership on an entity’s Board of Directors or advisory committees, Other: serves on Data and Safety Monitoring Boards; ALX Oncology: Research Funding.
